Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03447756
Other study ID # ABX-1431_PN014
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 2, 2017
Est. completion date May 7, 2019

Study information

Verified date July 2019
Source Abide Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to identify a titration regimen of ABX-1431 in adults with neuropathic pain with satisfactory tolerability to central nervous system (CNS) adverse events (AEs). During the course of this study, each participant will take a daily dose of ABX-1431 or a matching placebo for 28 days.


Description:

This is a double-blind, placebo-controlled, optimized titration study of ABX-1431 HCl. The study will explore whether patients experiencing ABX-1431-related CNS AE accommodate or become tolerant to them with continued dosing. The efficacy of ABX-1431 in treating neuropathic pain will be assessed by the change from baseline in pain intensity scores using numerical rating scale (NRS-11).

All patients will undergo a screening visit for enrollment criteria. Eligible patients will be treated with daily medication for 28 days which will include some treatment with placebo and some treatment with ABX-1431 HCl. Patients will record their daily average pain using a paper numerical rating scale (NRS-11).

This study will enroll up to 32 patients with peripheral neuropathic pain due to one of the four following diagnostic groups: post-herpetic neuralgia, diabetic peripheral neuropathy, small fiber neuropathy or post-traumatic neuropathic pain.


Recruitment information / eligibility

Status Completed
Enrollment 39
Est. completion date May 7, 2019
Est. primary completion date May 7, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria:

- Patient is a male or female over the age of 18 years of age at the Screening Visit.

- Patient has a peripheral neuropathic pain in one of the following diagnostic groups that is persistent for > 3 months

- Post-herpetic neuralgia

- Diabetic peripheral neuropathy

- Small fiber neuropathy

- Post-traumatic neuropathic pain

- Patient's median NRS-11 pain intensity score must be = 4 during the baseline period

- If a patient enters the trial on daily background neuropathic pain medications, then the patient must be on stable dose of medications for at least 30 days before enrollment and throughout the study.

- Patient is able to understand and comply with the protocol procedures for the entire trial and must give written informed consent.

- Men and Women must agree to a medically approved contraceptive regimen.

Key Exclusion Criteria:

- Patient is taking potent cytochrome P450 3A4/5 inducers or inhibitors

- Patient has received injection therapies (e.g., botulinum toxin, anesthetic or nerve block) or transcutaneous electrical stimulation to control pain in the past 60 days

- Patient has evidence of alcohol, drug or chemical abuse in the year before the Screening Visit.

- Patient is a lactating or pregnant female or a female who intends to become pregnant within 90 days following the last dose of investigational product.

- Patient has specific laboratory abnormalities

Other protocol-defined inclusion/exclusion criteria may apply.

Study Design


Intervention

Drug:
ABX-1431
Capsules of either 2mg, 10mg, or 50mg
Placebo oral capsule
placebo to match

Locations

Country Name City State
Moldova, Republic of Republican Clinical Hospital Chisinau

Sponsors (1)

Lead Sponsor Collaborator
Abide Therapeutics

Country where clinical trial is conducted

Moldova, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Identify a titration regimen of ABX-1431 The number of patients unable to continue due to central nervous system (CNS) adverse events (AEs) while exceeding mean plasma ABX-1431 AUC_0-24 of 190 ng*hr/ml or inhibiting 2-arachidonoylglycerol (2-AG) hydrolysis in peripheral blood mononuclear cells (PBMC) by more than 62% time-weighted inhibition over 24-hours. 28 days
Secondary Tolerance to ABX-1431 related CNS AEs determined by whether or not AEs resolve with continued dosing 28 days
Secondary Numerical Rating Scale (NRS-11) Change from Baseline in Pain Scores on the Numerical Rating Scale-11 (NRS-11) at 20 days. 20 days
See also
  Status Clinical Trial Phase
Recruiting NCT04638556 - Effect of Circulating lncRNAs on Type 2 Diabetic Peripheral Neuropathy
Completed NCT05580705 - Effects of Vibration Therapy in Addition to Routine Physical Therapy in Patients With Diabetic Neuropathy N/A
Terminated NCT01620775 - MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain N/A
Completed NCT02127762 - The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy N/A
Completed NCT00835757 - Diffusion Tensor Imaging of Sural Nerves in Diabetic Peripheral Neuropathy N/A
Recruiting NCT00553592 - Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes Phase 2
Recruiting NCT05863793 - Clinical Study of Acupuncture in the Treatment of Diabetic Peripheral Neuropathy N/A
Withdrawn NCT05041816 - Peripheral Nerve Responses to Focal Vibration and Implications in Pain and Mobility for Patients With Diabetic Peripheral Neuropathy N/A
Recruiting NCT06074562 - A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain Phase 2
Recruiting NCT04457531 - LiuWeiLuoBi Granule for the Treatment of Diabetic Peripheral Neuropathy Early Phase 1
Completed NCT02947828 - Polyneuropathy in Diabetes Mellitus Type 2
Completed NCT02056431 - Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy N/A
Completed NCT01681290 - Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes Phase 2
Completed NCT01474772 - Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN) Phase 3
Completed NCT01086150 - Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy Phase 2/Phase 3
Completed NCT04688671 - Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain Phase 2
Completed NCT04984044 - Effect of Vitamin D in Patients With Diabetic Peripheral Neuropathy to Alleviate Pain and Improvement of Symptoms N/A
Completed NCT06130917 - Effects of Multisystem Exercise on Balance, Postural Stability, Mobility and Pain in Patients With DPN. N/A
Completed NCT01496365 - Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy Phase 2
Completed NCT02337218 - Electrical Stimulation for Improving Balance in Diabetes N/A